RNAZ

Company Overview — What Does Transcode Therapeutics, Inc. Do?

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts. Transcode Therapeutics, Inc. (RNAZ) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Robert M. Dudley and employs approximately 9 people. With a market capitalization of $8M, RNAZ is one of the notable companies in the Healthcare sector.

Transcode Therapeutics, Inc. (RNAZ) Stock Rating — Reduce (April 2026)

As of April 2026, Transcode Therapeutics, Inc. receives a Reduce rating with a composite score of 27.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RNAZ ranks #3,828 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Transcode Therapeutics, Inc. ranks #645 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RNAZ Stock Price and 52-Week Range

Transcode Therapeutics, Inc. (RNAZ) currently trades at $8.21. The stock lost $0.34 (4.0%) in the most recent trading session. The 52-week high for RNAZ is $20.99, which means the stock is currently trading -60.9% from its annual peak. The 52-week low is $0.22, putting the stock 3638.6% above its annual trough. Recent trading volume was 11K shares, suggesting relatively thin trading activity.

Is RNAZ Overvalued or Undervalued? — Valuation Analysis

Transcode Therapeutics, Inc. (RNAZ) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.59x, versus the sector average of 2.75x.

At current multiples, Transcode Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Transcode Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Transcode Therapeutics, Inc. (RNAZ) earns a quality factor score of 9/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1650.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -450.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RNAZ Debt, Balance Sheet, and Financial Health

Transcode Therapeutics, Inc. has a debt-to-equity ratio of 267.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.60x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $3M.

RNAZ has a beta of 3.02, meaning it is more volatile than the broader market — a $10,000 investment in RNAZ would be expected to move 201.8% more than the S&P 500 on any given day. The stability factor score for Transcode Therapeutics, Inc. is 14/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Transcode Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Transcode Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-5.82. Net income for the quarter was $-24M. Operating income came in at $-14M.

In Q3 2025, Transcode Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-5.82. Net income for the quarter was $-5M. Operating income came in at $-5M.

In Q2 2025, Transcode Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-5.13. Net income for the quarter was $-4M. Operating income came in at $-4M.

In Q1 2025, Transcode Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.51. Net income for the quarter was $-12M. Operating income came in at $-3M.

Over the past 8 quarters, Transcode Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing RNAZ stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RNAZ Dividend Yield and Income Analysis

Transcode Therapeutics, Inc. (RNAZ) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RNAZ Momentum and Technical Analysis Profile

Transcode Therapeutics, Inc. (RNAZ) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 31/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

RNAZ vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Transcode Therapeutics, Inc. (RNAZ) ranks #645 out of 838 stocks based on the Blank Capital composite score. This places RNAZ in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RNAZ against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RNAZ vs S&P 500 (SPY) comparison to assess how Transcode Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

RNAZ Next Earnings Date

No upcoming earnings date has been announced for Transcode Therapeutics, Inc. (RNAZ) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RNAZ? — Investment Thesis Summary

The quantitative profile for Transcode Therapeutics, Inc. suggests caution. The quality score of 9/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Price momentum is positive at 63/100, suggesting the trend favors buyers. High volatility (stability score 14/100) increases portfolio risk.

In summary, Transcode Therapeutics, Inc. (RNAZ) earns a Reduce rating with a composite score of 27.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RNAZ stock.

Related Resources for RNAZ Investors

Explore more research and tools: RNAZ vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RNAZ head-to-head with peers: RNAZ vs AZN, RNAZ vs SLGL, RNAZ vs VMD.